New hope for patients with breast cancer … a tool for predicting the prospects and date of return of the tumor

Like many survivors of another type of cancer, survivors fear a new setback after their recovery, but researchers have developed a new tool to accurately predict the likely timing of the return of the disease, the site said. Medical News medical information.

The results of this study were published in the latest issue of Nature, the first of its kind, that predicts cancer in two decades.

A team of researchers from Cambridge University and Stanford University reported that there are 11 types of breast cancer, each with a different risk of relapse or relapse. The test will soon determine which women should be worry about the return of their cancer and which are at high risk of relapse. Cancer, and this prediction comes from the genetic makeup of tumors.

The team used the genetic makeup of nearly 2,000 breast cancer patients and followed an average of 14 years, the team said, which is currently simplifying the test so doctors can easily use the test on their patients.

The researchers said the simplest and easiest version could be available in the next five years. According to Professor Carlos Caldas, a senior researcher at the Cambridge Institute for Cancer Research in the UK, "Breast cancer treatments have improved dramatically in recent years." For some women, cancer breast returns and spreads and becomes insurmountable. "

"In this study, we have deepened the molecular subtypes of breast cancer so that we can more accurately identify people at risk of relapse and discover new ways to treat them," said Caldas.

"We have made it clear that the molecular nature of breast cancer in women determines how their disease can develop not only in the first five years, but also later, and we hope that our research tool will be transformed into A test that doctors can easily use to guide treatment recommendations "to the size of the tumor, where the aggressiveness, age of the patient and the type of tumor are used to predict a relapse".

One of the most lethal forms of breast cancer is triple negative cancer, said Rueda. However, if the patient survives the first five years of diagnosis and treatment, the risk of cancer recurrence is minimal, while some cancers have a genetic image making his return within 20 years a 50% probability.

He confirmed that there are 8 types of positive estrogen-receptor cancers, four of which have a good chance of not re-offending within 20 years, while the other four run a significant risk of relapse from 40% to 62%.

The team finds that triple negative cancer is more likely to spread to the brain, while cancer-positive estrogen receptors and the negative cancer "HER2" are more likely to spread to the bones.